IRWD — Ironwood Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $582.39m
- $1.03bn
- $351.41m
- 35
- 89
- 99
- 88
Annual cashflow statement for Ironwood Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 106 | 528 | 175 | -1,032 | 0.88 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 60 | 47.5 | 28.7 | 1,129 | 31.8 |
| Discontinued Operations | |||||
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.941 | 17.7 | 2.82 | 11.3 | 0.739 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | 169 | 262 | 274 | 183 | 104 |
| Capital Expenditures | -1.84 | -0.265 | -0.136 | -1,026 | -0.142 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | — | 0 | — | — | — |
| Sale of Fixed Assets | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -1.84 | -0.265 | -0.136 | -1,026 | -0.142 |
| Financing Cash Flow Items | — | 0 | — | -29.2 | -2.98 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 18.5 | -4.55 | -238 | 277 | -107 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 186 | 257 | 36.1 | -566 | -3.6 |